UCB (OTCMKTS:UCBJF) Sees Strong Trading Volume – Time to Buy?

UCB SA (OTCMKTS:UCBJF) shares saw unusually-high trading volume on Wednesday . 7,591 shares changed hands during trading, an increase of 986% from the previous session’s volume of 699 shares.The stock last traded at $295.59 and had previously closed at $287.84.

Wall Street Analyst Weigh In

Separately, Piper Sandler reiterated a “neutral” rating on shares of UCB in a research note on Wednesday, July 22nd. Six analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.

UCB Stock Down 12.2%

The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. The company’s fifty day moving average price is $292.35 and its 200 day moving average price is $300.27.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.